Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients - Full Text View

Purpose

In HIV infected patients, individuals exposed to the virus of Hepatitis B are more susceptible to develop a chronic and severe liver disease with a major risk of cirrhosis and liver cancer.

However, the existing protocol of vaccination against Hepatitis B is less efficient in HIV-infected patients than in non HIV-infected-patients, and, in case of response, its longevity has to be followed up carefully. This study compares the efficacy of the standard protocol vaccination with GenHevac-B and 2 other protocols, a double-dose of GenHevac-B and a set of intradermal injections of Genhevac-B, in HIV-infected patients with lymphocytes T CD4 level above 200 permm3.

Condition	Intervention	Phase
HIV Infections	Biological: GenHevac B Pasteur	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention
Official Title:	Open-label, Randomized, and Multicentric Phase III Clinical Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV-1-infected Patients With CD4-positive T-lymphocytes Counts Above 200 permm3 ANRS HB 03 VIHVAC-B

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS Hepatitis Hepatitis A Hepatitis B

U.S. FDA Resources

Further study details as provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):

Primary Outcome Measures:

HIV-infected patients who seroconvert in the first two months after the last vaccination. Seroconversion is defined as antibodies AbHBs titers equal or above 10 mUI per ml. [ Time Frame: two months after the last injection;week 28, month 18, month 30 and month 42 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

According to the vaccine administration (IM or ID) comparison of AbHBs titers,permanence of the humoral response,intensity of clinical and biological events and predicting factors related to seroconversion [ Time Frame: two months after the last injection; week 28, month 18, month 30 and month 42 ] [ Designated as safety issue: Yes ]


Enrollment:	437
Study Start Date:	June 2007
Study Completion Date:	September 2012
Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: A GenHevac-B 20 microgramme Intramuscular use at M0, M1, M6	Biological: GenHevac B Pasteur Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6 Other Name: Sanofi Pasteur MSD
Experimental: B GenHevac-B 40 microgramme Intramuscular use at M0, M1, M2, M6	Biological: GenHevac B Pasteur Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6 Other Name: Sanofi Pasteur MSD
Experimental: C GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6	Biological: GenHevac B Pasteur GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6 Other Name: Sanofi Pasteur MSD

Detailed Description:

Comparison of 3 vaccination strategy against Hepatitis B in patients with HIV infection T CD4 above 200 per mm3

Intervention:

Arm A: GenHevac-B 20 microgramme Intramuscular use at M0, M1, M6
Arm B: GenHevac-B 40 microgramme Intramuscular use at M0, M1, M2, M6
Arm C: GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age Eligible for Study: 18 years - NA, Genders Eligible for Study: Both

Criteria

Inclusion criteria:

HIV infection
T CD4 count cell level above 200 per mm3
Serology Hepatitis B negative (AgHBs, AbHBs and AbHBc negative)
unchanged ARV for the last 3 months for patients who are receiving ARV at the screening visit
Undetectable for the last 6 months with ARV for any patient with T CD4 level below 350 per mm3
Pregnancy test negative at the screening and inclusion visits

Exclusion Criteria:

Any injection of the vaccine against Hepatitis B in the medical history
Acute cytolysis in the last 3 months with transaminases equal or above 5 times the upper normal range for HIV-HCV coinfected patients, or transaminases equal or above 2 times the upper normal for non coinfected patients
Any vaccine received one month before the inclusion
History of intolerance to any component of GenHevac-B
Evolutive opportunistic infection treated the month before the screening visit
Severe and acute pyretic infection or unexplained fever the week before inclusion
Evolutive hemopathy or solid-organ cancer
Prothrombin factor equal or below 50 percent and/or platelets equal or below 50 000 per mm3
Immunosuppressive treatment or general corticotherapy (equal or above 0,5 mg per kg per day during above 7 days) in the last 6 months before the screening visit
Previous Immunomodulating treatment (interferon, interleukin-2,etc) or plan in the next 6 months
Splenectomy
Decompensated cirrhosis (Child Pugh B or C)
Kidney deficient function (creatinine clearance below 50 ml per mn)
Other immunocompromised condition not related to HIV infection (solid-organ transplantation, chemotherapy in the last 6 months)
Any participation to another clinical trial plan until Week 28

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00480792

Locations


France
Hopital Cochin CIC de vaccinologie
Paris, France, 75014

Sponsors and Collaborators

French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)

Sanofi Pasteur MSD

Investigators


Principal Investigator:	Odile Launay, MD	CIC de vaccinologie Cochin-Pasteur 27, rue du Fb Saint Jacques 75014 Paris Fr
Study Chair:	Fabrice Carrat, MD	Inserm U707 27, rue de Chaligny 75571 Paris cedex 12 Fr

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, Colin de Verdière N, Slama L, Martin K, Lortholary O, Carrat F; ANRS HB03 VIHVAC-B Trial. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA. 2011 Apr 13;305(14):1432-40. doi: 10.1001/jama.2011.351.


Responsible Party:	French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
ClinicalTrials.gov Identifier:	NCT00480792 History of Changes
Other Study ID Numbers:	2006-003940-50 ANRS HB 03 VIHVAC-B
Study First Received:	May 30, 2007
Last Updated:	July 22, 2013
Health Authority:	France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS):


Hepatitis B vaccination GenHevac-B Pasteur HIV Infections

Additional relevant MeSH terms:


Hepatitis HIV Infections Hepatitis B Liver Diseases Digestive System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral	Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Hepadnaviridae Infections DNA Virus Infections Hepatitis, Viral, Human Vaccines Immunologic Factors Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 28, 2016

Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients (VIHVAC-B)